Minerva Neurosciences (NERV) Income from Continuing Operations (2013 - 2026)
Minerva Neurosciences (NERV) posted Income from Continuing Operations of 32311950.0 for Q1 2026, down 466.37% on a QoQ basis from 5705066.0 in Q4 2025, and down 762.9% year-over-year from 4874365.64 in Q1 2025.
Minerva Neurosciences (NERV) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 32311950.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 762.9% year-over-year to 32311950.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43992202.0 (down 143.59% YoY) and the FY2025 annual result came in at 113825531.0, up 2.4% from the prior year.
- Income from Continuing Operations was 32311950.0 for Q1 2026 at Minerva Neurosciences, down from 5705066.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2737708.0 in Q3 2025 and bottomed at 103680119.0 in Q4 2023.
- A 5-year average of 17968126.12 and a median of 5933813.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 95.83% — and 2026, when it slumped 762.9%.
- Minerva Neurosciences' Income from Continuing Operations stood at 94881575.0 in 2022, then decreased by 9.27% to 103680119.0 in 2023, then surged by 95.83% to 4328431.0 in 2024, then slumped by 31.8% to 5705066.0 in 2025, then sank by 466.37% to 32311950.0 in 2026.
- Business Quant data shows NERV's Income from Continuing Operations at 32311950.0 in Q1 2026, 5705066.0 in Q4 2025, and 2737708.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -32.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.31 Mn |
| Dec 31, 2025 | -5.71 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -3.24 Mn |
| Mar 31, 2025 | -3.74 Mn |
| Dec 31, 2024 | -4.33 Mn |
| Sep 30, 2024 | -4.05 Mn |
| Jun 30, 2024 | -5.93 Mn |
| Mar 31, 2024 | -6.32 Mn |
| Dec 31, 2023 | -103.68 Mn |
| Sep 30, 2023 | -6.77 Mn |
| Jun 30, 2023 | -6.18 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -94.88 Mn |
| Sep 30, 2022 | -5.66 Mn |
| Jun 30, 2022 | -6.89 Mn |
| Mar 31, 2022 | -8.04 Mn |
| Dec 31, 2021 | -21.37 Mn |
| Sep 30, 2021 | -7.71 Mn |
| Jun 30, 2021 | -8.98 Mn |